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ABSTRACT
Human immunodeficiency virus (HIV)-associated neurocognitive disorders are the main 
cause of cognitive decline and dementia in people living with HIV (PLHIV). However, 
extensive workup should be done in patients with rapidly progressive dementia (RPD) and 
HIV, especially when secondary infection in the central nervous system (CNS) is ruled out. 
Sporadic Creutzfeldt-Jakob disease (sCJD) is the main cause of RPD in non-HIV patients. It 
is a fatal neurodegenerative condition caused by prions that mainly affects elderly patients. 
Our objective is to describe two cases of PLHIV presenting with controlled infections and 
sCJD, and to review the literature. Our patients were younger than expected for sCJD and 
one of them had a longer disease course. As aging is expected to occur earlier in PLHIV, 
sCJD must be excluded in younger PLHIV presenting with RPD and without CNS infection.
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INTRODUCTION 
The most prevalent cognitive disorders in people living with human 
immunodeficiency virus – HIV (PLHIV) are HIV-associated neurocognitive 
disorders (HAND). However, rapidly progressive dementia (RPD) in this population 
should be investigated in the same way as in seronegative individuals.
The leading cause of RPD are prion diseases (PD), mostly sporadic Creutzfeldt-
Jakob disease (sCJD). PD are neurodegenerative disorders caused by the conversion 
of a normal cellular prion protein (PrPC) into its abnormal and pathogenic form 
called prion. The median age at onset of symptoms is 67 years, ranging from 55 to 
75 years, with a median survival of five months1.
We describe the rare association of two clinical conditions: sCJD and HIV 
infection in two patients with clinically-controlled HIV, undetectable viral load and 
no history of opportunistic CNS infection. In addition, we reviewed the literature 
and compared our cases to previously published ones that are only five, to date2-6.
CASE REPORT
Patient 1 was a 52 years old man whose HIV infection was diagnosed in 
2000, presenting with a controlled disease since then, without opportunistic CNS 
infections. In June 2018, he had an insidious behavior change, insomnia and 
difficulties at work. His neurological examination revealed a global cerebellar 
syndrome, bilateral Babinski, 4-limb paratonia and release of face axial reflexes. 
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The cognitive evaluation showed memory, attention and 
executive function deficits.
The electroencephalogram (EEG) was normal; the 
cerebrospinal fluid (CSF) analysis revealed an undetectable 
HIV viral load and normal protein level and positive14.3.3 
protein. The brain magnetic resonance imaging (MRI) 
showed bilateral hyper intensity of images in caudal nuclei 
during the fluid acquisition inversion recovery (FLAIR) and 
diffusion-weighted imaging (DWI) sequences; the prion 
protein gene (PRNP) analysis excluded the presence of 
mutations and codon 129 was heterozygous (M129V). He 
died in July 2019, 13 months after the initial symptoms. 
Patient 2, a 61 years old man, diagnosed with HIV 
infection in 1997, presenting with a controlled disease 
since then, without any opportunistic infection. In 
February 2019, he reported asthenia, lack of appetite, 
difficulty sleeping and occasional memory lapses. Two 
months later, he evolved with uncoordinated steps and the 
need of support to walk, in addition to visual delusions 
and bladder incontinence. 
His neurological examination revealed four limbs 
paratonia and a global cerebellar syndrome, aside from 
lower limbs hyporeflexia. The cognitive evaluation showed 
dementia associated with a dysexecutive syndrome and also 
episodic memory and attention deficits. 
His MRI showed bilateral asymmetric cortical ribboning 
in the cerebral cortex at DWI and FLAIR. Bilateral thalami 
and striatum hyper intense images, with an anterior to 
posterior gradient were also observed at DWI (Figure 1) 
and FLAIR (Figure 2). The CSF analysis revealed elevated 
protein (85 mg/dL), undetectable HIV viral load, elevated 
Tau protein (2,520 pg/mL), positive 14.3.3 protein and 
detection of prion by real-time quaking induced conversion 
(RT-QuIC). He died five months after the initial symptoms.
DISCUSSION
In the face of RPD in PLHIV, classical causes of 
cognitive impairment in this population should be ruled out, 
but it is extremely important to consider other diagnoses 
that are not directly linked to HIV. 
Creutzfeldt-Jakob disease (CJD) is a rare, fatal and 
neurodegenerative disease classically characterized by 
rapidly progressive dementia and ataxia, extrapyramidal or 
pyramidal symptoms and myoclonus. The disease may occur 
in sporadic, genetic and acquired forms7. Sporadic forms 
account for 85% of CJD cases. The neurological impairment 
(extrapyramidal, pyramidal, cerebellar, visual disturbances), 
myoclonus and akinetic mutism are part of clinical diagnostic 
criteria8-11. The causative agent is called prion (or scrapie 
prion protein, PrPsc), a pathogenic form of the normal cellular 
prion protein (PrPc). The conversion of PrPc to PrPsc leads 
to neurodegeneration and neuronal death6. 
According to the World Health Organization - WHO 
(1998), possible sCJD are those with progressive dementia, 
symptoms that progress in less than two years, with at least 
two out of the four clinical features: 1) myoclonus, 2) visual 
or cerebellar disturbance, 3) pyramidal/extrapyramidal 
dysfunction, and 4) akinetic mutism; probable sCJD are 
those possible CJD clinical criteria and subsidiary positive 
tests (typical EEG or 14.3.3 protein in CSF analysis)8. 
The University of California criteria (2007) define 
probable cases of sCJD as those with rapid cognitive 
decline associated with at least two specific neurological 
Figure 1 - Diffusion-weighted imaging (DWI) - bilateral restricted 
diffusion cortical ribboning is shown in frontal, temporal and 
parietal cortices, also in the insula, most evident on the right. 
Similar alteration of the signal affects the thalamus, lentiform 
nuclei and caudate nucleus, mainly on the right.
Figure 2 - Fluid acquisition inversion recovery (FLAIR) 
sequences - asymmetric hyperintensities in the cerebral cortex, 
most evident on the right. Alterations are also seen in nuclei of 
the base and thalamus, bilaterally. Note that hyper intensities 
are brighter in DWI acquisition than in FLAIR sequence. 
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manifestations: myoclonus, pyramidal or extrapyramidal, 
visual, cerebellar, akinetic mutism or other focal higher 
cortical sign and at least one of ancillary tests: typical EEG 
or positive MRI; routine investigations that do not suggest 
an alternative diagnosis9.
According to the European criteria (2017), sCJD 
probable cases are classified in the presence of a 
rapidly progressive cognitive impairment and two of the 
characteristic neurological impairment signs, in addition 
to symptoms from WHO criteria associated with either 
typical EEG, or typical MRI change or CSF protein 14.3.3 
positivity, or any progressive neurological syndrome 
associated with positive RT-QuIC10. 
Restriction of diffusion in the basal ganglia and/or more 
than one cortical region, absence of contrast enhancement, 
and absence of white matter involvement strongly suggest 
the diagnosis of CJD in a patient with an appropriate clinical 
context12. 
The typical EEG shows generalized periodic discharges. 
Diffuse disruption of the brain electrical activity or periodic 
lateralized discharges are observed in some cases3.
The presence of the 14.3.3 protein and high levels of 
total tau protein in the CSF analysis supports the diagnosis.
The histopathological analysis shows neuronal loss, 
gliosis and spongiform vacuolization in the absence 
of inflammatory response12. In all criteria, defined 
CJD requires the presence of prion within the CNS 
tissue, confirmed either by immunohistochemical or by 
biochemical techniques. 
More recently, a technique for identifying prion in vivo 
called RT-QuIC has been developed. In a recent study of 
the National Prion Disease Pathology Surveillance Center 
of the United States of America13 that analyzed 10,498 CSF 
specimens, the sensitivity was 90.3% and specificity 98.5% 
for CJD diagnosis by a second-generation RT-QuIC. This 
technique became a useful tool for the in vivo diagnosis 
of CJD.
Nowadays, because of the wide distribution of 
antiretroviral therapy to PLHIV worldwide and successful 
immune reconstitution among this population, significantly 
lower incidences of opportunistic infections and mortality 
rates are observed. Currently, HIV treatment promotes 
longer survival rates, closing the life expectancy gap 
between infected and uninfected individuals14-16.
The life expectancy and consequently aging have 
increased in prevalence in HIV among the elderly17 and 
a simultaneous increase in the number of HIV patients 
suffering from chronic diseases typical of this age group18, 
such as diabetes, cardiovascular and neurodegenerative 
disorders has appeared
The way HIV, as well as antiretroviral drugs, have 
influenced chronic diseases of the elderly, particularly 
neurological ones need to be better understood. Potentially, 
these patients are under higher risk of vascular events19 and a 
reduction in the subcortical and cortical volume is observed 
with aging, and there seems to be a greater reduction of 
the cortical volume in older PLHIV, in comparison with 
HIV-negative individuals of the same age20.
Considering the seven cases of sCJD in PLHIV, five of 
the literature, in addition to those reported in this article, six 
of them were below the mean and median age of onset of 
symptoms reported to non-HIV patients, which is 64 and 
67 years old, respectively. Two patients had longer survival 
than expected in the general population with prion disease 
and all the patients with long-term HIV infections were well 
controlled. Only one patient had the onset of RPD symptoms 
a few months after the diagnosis of HIV infection6. Table 1 
summarizes the comparison of cases of sCJD in PLHIV.
We consider that HIV and CJD are non-communicable 
diseases and the younger age of onset of CJD in PLHIV is 
Table 1 - Comparison of seven cases of sporadic Creutzfeldt-Jakob disease, in people living with the human immunodeficiency 
virus (HIV). 
Case Age (years)
Time of HIV infection 
(months)
Evolution time to 
death (months)
Diagnostic criteria Reference 
1 66 240 3 Definite case Babi et al.2
2 59 3 2 Definite case Eimer et al.3
3 62 360 4 Definite case Abu-Rumeileh et al.4
4 63 36 10 Definite case van de Ven et al.5
5 52 Not available
2 months after 
hospitalization. 
Total illness time not 
available
Probable sCJD Carvalho Neto et al.6
6 52 228 13 Probable sCJD This study
7 61 288 5 Probable sCJD This study
HIV = human immunodeficiency virus; sCJD = sporadic Creutzfeldt-Jakob disease.
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associated with a higher vulnerability of these elder patients to 
neurodegenerative diseases, but this case report is insufficient 
to rule out a causative association between both diseases.
CONCLUSION
Living with HIV has become a chronic medical condition 
with a longer life expectancy. PLHIV nowadays are more 
susceptible to neurodegenerative conditions associated with 
aging, and few cases of sCJD in PLHIV patients have been 
described so far. The association between these conditions 
remains unclear. It is important that physicians, especially 
infectious disease specialists and neurologists, be aware 
of the multiple etiologies of RPD, including sCJD in this 
particular population. 
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